Clinical Trial Update: Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated alemtuzumab (Campath) for T-LGL lymphoproliferative disorders and has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-large Granular Lymphocytic Leukemia
• T-lymphoproliferative Disorder

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: T-LGL Lymphoproliferative Disorders | Phase 2 | Status: COMPLETED | Results posted: 2019-05-03